At Belhaven Biopharma, our focus extends beyond immediate solutions to pioneering a future where emergency medications are more affordable, effective, and user-friendly.
Our mission is to ensure that life saving medications are universally accessible and simpler to use through the development of dry powder nasal formulations.
At Belhaven, we are dedicated to developing cutting-edge medical solutions that transform emergency care. Our technology is designed to meet the highest standards of efficiency, reliability, and accessibility. As we push the boundaries of traditional treatment methods, we remain focused on delivering life-saving products that not only disrupt the market but also meet the evolving needs of healthcare systems worldwide.
Belhaven’s leadership team comprises experts with decades of experience in the pharmaceutical and biotech industries, all focused on creating safe and effective treatments.
Chief Executive Officer and Chairman of the Board
Scott Lyman is the CEO and a Co-Founder of Belhaven Biopharma and serves as Chairman of the Board. Prior to founding Belhaven, he was the Chief Business Officer of Grid Therapeutics, a spinout from Duke University. Scott has previously held leadership roles at GSK, BioCryst, and Salix. His prior experience includes developing spray dried powders, leading drug development teams, participating in FDA filings, and the licensing of multiple products. In these roles, Scott contributed to the approvals of new Enbrel dosage forms, epilepsy medicine Ezogabine, antibiotic Xifaxan, and HIV medicine Tivicay. Mr. Lyman holds a BS in Chemical Engineering from Iowa State University, a MS in Chemical Engineering from the University of Colorado at Boulder, and an MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill.
Chief Financial Officer and Board Member
Dave Neal is the CFO and a Co-Founder of Belhaven Biopharma and serves as a Board Member. Mr. Neal is a leading expert on the intersection of startups, law, and finance. As a result of his more than two decades as a founder, C-level team member and financier of early-stage companies, he has amassed broad experience in all sectors of the startup landscape. He has managed over $300 million in financing during his career. In addition to his corporate roles, Dave has been a Professor of Entrepreneurship at the Kenan-Flagler Business School at UNC for more than twenty years and served for five years as an Adjunct Professor of Law at the UNC School of Law. Mr. Neal holds a BS and a JD from the University of North Carolina at Chapel Hill, and an MBA from Stanford University.
Chief Operations Officer
Brian Taubenheim joined Belhaven Biopharma in 2022 as the Chief Operations Officer with the goal of transitioning the company from pre-clinical development to an organization capable developing a portfolio of assets through the clinic to marketing authorization. Prior to joining Belhaven, he founded and grew Wilco Consulting over the course of 9 years providing operational, technical, and data science services to startup and multinational companies in and adjacent to the pharmaceutical sector. Mr. Taubenheim started his professional career in the CDMO industry and transitioned into pharmaceuticals holding roles in CMC development, operations management, business development, and therapeutic program lead. During that time, he had the opportunity to work with partner companies and Agencies in the US, Europe, Canada, and Asia-Pacific. He has led and worked on programs with the US Biomedical Advanced Development Authority, National Institutes of Health, and Department of Defense from initial funding to supply of the Strategic National Stockpile. Mr. Taubenheim is a veteran of the US Marine Corps, holds a bachelor’s degree in chemistry from Lakeland University, master’s degree in business administration from Cardinal Stritch University, master’s certification in project management from the University of Wisconsin, and master’s degree in data science from Northwestern University.
Our board and advisors provide strategic oversight, ensuring we consistently deliver to the highest standards in healthcare innovation.
Founder/CSO, Oriel Therapeutics & Founder/CEO of Cirrus Pharmaceuticals (both acquired)
Partner at The ExCo Group. and Director at FaZe Clan; Previously Senior Vice President & Chief Financial Officer, Disney Interactive Media Group
Global VP, Asia Pacific, Aptar CSP Technologies; Over 15 years experience with device/drug combo products
Dept. Chair, Univ. of New Mexico School of Pharmacy; Pioneer in research on nasal delivery of epinephrine
Leads one of the largest allergy practices in North Carolina
Pediatric Radiologist at Duke University; Patient Advocate
Assoc. Prof. of Medicine & Peds, UNC School of Med; Division Chief, UNC Pediatric Allergy & Immunology; Director, UNC Food Allergy Initiative and Medical